• +1-646-491-9876
    • +91-20-67278686

    Search

    Pertussis Pipeline Review H1 2017

    Pertussis Pipeline Review H1 2017

    • Report Code ID: RW0001858670
    • Category Pharmaceuticals
    • No. of Pages 96
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Pertussis (Whooping Cough) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

    Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 8, 5, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

    Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Pertussis (Whooping Cough) - Overview
    Pertussis (Whooping Cough) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Pertussis (Whooping Cough) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development
    Beijing Minhai Biotechnology Co Ltd
    Bharat Biotech International Ltd
    Biological E Ltd
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    DBV Technologies SA
    GlaxoSmithKline Plc
    Green Cross Corp
    Indian Immunologicals Ltd
    Kaketsuken KK
    LG Chem, Ltd.
    NanoBio Corp
    Sanofi
    Sanofi Pasteur SA
    Serum Institute of India Ltd
    Shantha Biotechnics Pvt Ltd
    Synthetic Biologics Inc
    Zydus Cadila Healthcare Ltd
    Pertussis (Whooping Cough) - Drug Profiles
    (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) ) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (hepatitis B + pertussis) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BK-1310 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bladder cancer + pertussis + tuberculosis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVN-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DTaP-IPV-HB-PRPT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-3111A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KD-370 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LBVD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis (acellular) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis (acellular) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis (whole cell) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis [strain BPZE1] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SYN-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VN-0105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Pertussis (Whooping Cough) - Dormant Projects
    Pertussis (Whooping Cough) - Discontinued Products
    Pertussis (Whooping Cough) - Product Development Milestones
    Featured News & Press Releases
    Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
    Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
    Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
    Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
    Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
    Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination
    Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
    Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough
    Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine
    Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
    Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
    Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
    Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
    Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
    Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Pertussis (Whooping Cough) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H1 2017
    Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H1 2017
    Pertussis (Whooping Cough) - Pipeline by LG Chem, Ltd., H1 2017
    Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Sanofi, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H1 2017
    Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Pertussis (Whooping Cough) - Dormant Projects, H1 2017
    Pertussis (Whooping Cough) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Pertussis (Whooping Cough) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Pertussis (Whooping Cough) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Beijing Minhai Biotechnology Co Ltd
    Bharat Biotech International Ltd
    Biological E Ltd
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    DBV Technologies SA
    GlaxoSmithKline Plc
    Green Cross Corp
    Indian Immunologicals Ltd
    Kaketsuken KK
    LG Chem, Ltd.
    NanoBio Corp
    Sanofi
    Sanofi Pasteur SA
    Serum Institute of India Ltd
    Shantha Biotechnics Pvt Ltd
    Synthetic Biologics Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//pertussis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//pertussis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//pertussis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments